Search results for "VASCULAR DAMAGE"

showing 10 items of 26 documents

Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011:current status in 37 ESC countries

2014

Item does not contain fulltext AIMS: Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion therapy in ST-elevation myocardial infarction (STEMI). We conducted this study to evaluate the contemporary status on the use and type of reperfusion therapy in patients admitted with STEMI in the European Society of Cardiology (ESC) member countries. METHODS AND RESULTS: A cross-sectional descriptive study based on aggregated country-level data on the use of reperfusion therapy in patients admitted with STEMI during 2010 or 2011. Thirty-seven ESC countries were able to provide data from existing national or regional registries. In countries where no such registries exist, dat…

AdultMalemedicine.medical_specialtyCross-sectional studymedicine.medical_treatmentVascular damage Radboud Institute for Health Sciences [Radboudumc 16]PopulationCardiologyMyocardial Infarctionacute myocardial infarction610 Medicine & healthMyocardial ReperfusionPercutaneous Coronary InterventionReperfusion therapyHumansMedicineThrombolytic TherapyIn patientHospital MortalityRegistriescardiovascular diseasesMyocardial infarctioneducationAgededucation.field_of_studybusiness.industryST elevationCoronary Care UnitsPercutaneous coronary interventionThrombolysisMiddle Agedmedicine.disease3. Good healthEuropeCross-Sectional Studiessurgical procedures operativeEmergency medicineWorkforceFemaleHuman medicineMedical emergencyCardiology and Cardiovascular Medicinebusiness
researchProduct

Early Vascular Aging in Normotensive Patients With Systemic Lupus Erythematosus

2015

Connective tissue diseases, like systemic lupus erythematosus (SLE), are associated with early and accelerated atherosclerosis. Recently, the concept of “early vascular aging” (EVA) has been more widely accepted. Aortic stiffness is one of the important markers of EVA. We evaluated EVA and subclinical atherosclerosis, by measuring aortic pulse wave velocity (aPWV) and carotid intima–media thickness (cIMT), in 50 normotensive patients with SLE (mean age: 39 ± 12 years). We compared these participants with 50 age- and sex-matched patients with essential hypertension (EH) and 20 healthy controls. Each participant underwent 24-hour ambulatory blood pressure monitoring (ABPM), aPWV, and cIMT me…

Carotid Artery DiseasesMaleSettore MED/09 - Medicina InternaSLEBlood Pressure030204 cardiovascular system & hematologyEssential hypertensionCarotid Intima-Media Thickness0302 clinical medicineRisk FactorsLupus Erythematosus SystemicUltrasonography Doppler Colorskin and connective tissue diseasesPulse wave velocityAge FactorsBlood Pressure Monitoring AmbulatoryMiddle Agedcardiovascular systemCardiologyFemaleVascular agingAortic stiffnessEssential HypertensionCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyAmbulatory blood pressurePulse Wave AnalysisRenal Circulation03 medical and health sciencesVascular StiffnessInternal medicinemedicineHumansIn patientSettore MED/14 - Nefrologia030203 arthritis & rheumatologyAccelerated atherosclerosisbusiness.industryAtherosclerosismedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareSettore MED/16 - ReumatologiaCase-Control StudiesSubclinical atherosclerosisAsymptomatic DiseasesVASCULAR DAMAGEAORTIC STIFFFNESSEARLY VASCULAR AGINGVascular ResistancebusinessAngiology
researchProduct

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

2015

Background— Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. Methods and Results— We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of med…

Angiotensin receptorVascular damage Radboud Institute for Health Sciences [Radboudumc 16]receptorsTetrazolesheart failureAngiotensin-Converting Enzyme InhibitorsKaplan-Meier EstimateSacubitrilAngiotensin; Heart failure; Neprilysin; Receptors; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Double-Blind Method; Enalapril; Heart Failure; Humans; Kaplan-Meier Estimate; Natriuretic Peptide Brain; Neprilysin; Peptide Fragments; Risk Factors; Stroke Volume; Survivors; Tetrazoles; Treatment Outcome; Troponin; Disease Progression; Medicine (all); Cardiology and Cardiovascular Medicine; Physiology (medical)AngiotensinEnalaprilRisk FactorsEnalapril/therapeutic useNatriuretic Peptide BrainHeart Failure/bloodSurvivorsReceptorNeprilysinAminobutyrates: Systèmes cardiovasculaire & respiratoire [D03] [Sciences de la santé humaine]Troponin/bloodTroponinAngiotensin Receptor Antagonists/therapeutic useDrug CombinationsAngiotensin-Converting Enzyme Inhibitors/therapeutic useTreatment OutcomeTetrazoles/therapeutic useCardiologyDisease ProgressionValsartanNeprilysinHeart Failure/blood/drug therapy/physiopathologyCardiology and Cardiovascular Medicinemedicine.drugReceptormedicine.medical_specialtyHeart failureneprilysinAngiotensin Receptor Antagonistsreceptors angiotensinDouble-Blind MethodPhysiology (medical)Internal medicineRenin–angiotensin systemmedicineHumansheart failure neprilysin receptors angiotensinEnalaprilbusiness.industryBiphenyl CompoundsStroke Volumemedicine.diseasePeptide FragmentsEndocrinologyAminobutyrates/therapeutic useStroke Volume/physiologyHeart failureNatriuretic Peptide Brain/blood: Cardiovascular & respiratory systems [D03] [Human health sciences]businessNeprilysin/antagonists & inhibitorsPeptide Fragments/bloodSacubitril ValsartanBiomarkersBiomarkers/blood
researchProduct

The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.

2014

Item does not contain fulltext Plasma triglyceride concentration is a biomarker for circulating triglyceride-rich lipoproteins and their metabolic remnants. Common mild-to-moderate hypertriglyceridaemia is typically multigenic, and results from the cumulative burden of common and rare variants in more than 30 genes, as quantified by genetic risk scores. Rare autosomal recessive monogenic hypertriglyceridaemia can result from large-effect mutations in six different genes. Hypertriglyceridaemia is exacerbated by non-genetic factors. On the basis of recent genetic data, we redefine the disorder into two states: severe (triglyceride concentration >10 mmol/L), which is more likely to have a mono…

Multifactorial InheritanceSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Genome-wide association studyDisease030204 cardiovascular system & hematologyISCHEMIC-HEART-DISEASEBioinformaticshypertriglyceridaemia0302 clinical medicineEndocrinologyGENERAL-POPULATIONHypertriglyceridemiatreatmentmedicine.diagnostic_testREMNANT CHOLESTEROLCombined Modality Therapy3. Good healthLIPASE DEFICIENCYdiagnosiPLASMA TRIGLYCERIDESDENSITY-LIPOPROTEIN CHOLESTEROLCARDIOVASCULAR-DISEASEPractice Guidelines as TopicBiomarker (medicine)Multifactorial Inheritancemedicine.medical_specialty030209 endocrinology & metabolismHealth PromotionArticle03 medical and health sciencesPharmacotherapyInternal medicineInternal MedicinemedicineAnimalsHumansHOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIAGenetic Predisposition to DiseaseAlleleGENOME-WIDE ASSOCIATIONLife Stylehypertriglyceridaemia; diagnosis; treatmentTriglyceridesGenetic testingbusiness.industryHypertriglyceridemianutritional and metabolic diseasesmedicine.diseaseEndocrinologyNONFASTING TRIGLYCERIDESbusinessBiomarkersThe lancet. Diabetesendocrinology
researchProduct

COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction

2022

ObjectiveThe initial data of the International Study on Acute Coronary Syndromes - ST Elevation Myocardial Infarction COVID-19 showed in Europe a remarkable reduction in primary percutaneous coronary intervention procedures and higher in-hospital mortality during the initial phase of the pandemic as compared with the prepandemic period. The aim of the current study was to provide the final results of the registry, subsequently extended outside Europe with a larger inclusion period (up to June 2020) and longer follow-up (up to 30 days).MethodsThis is a retrospective multicentre registry in 109 high-volume primary percutaneous coronary intervention (PPCI) centres from Europe, Latin America, S…

RegistrieMaleST Elevation Myocardial Infarction/diagnosisTime FactorsPercutaneousmedicine.medical_treatmentVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Coronary Artery DiseasePractice Patterns030204 cardiovascular system & hematologyRate ratioTime-to-Treatment/trendsCardiologists0302 clinical medicineRetrospective StudieHeart RateRisk FactorsPandemicST segmentRegistriesHospital Mortality030212 general & internal medicineMyocardial infarctionPractice Patterns Physicians'10. No inequalityPercutaneous Coronary Intervention/adverse effectsHospital Mortality/trendsCOVID-19; myocardial infarction; percutaneous coronary interventionIncidenceIncidence (epidemiology)*percutaneous coronary interventionMiddle Aged3. Good healthTreatment Outcomemyocardial infarctionCardiologyFemale*COVID-19Cardiology and Cardiovascular MedicineCardiologists/trendsHumanCOVID-19; myocardial infarction; percutaneous coronary intervention; Aged; Cardiologists; Female; Hospital Mortality; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Practice Patterns Physicians'; Registries; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Time-to-Treatment; Treatment Outcome; COVID-19medicine.medical_specialtyTime FactorCoronavirus disease 2019 (COVID-19)CardiologistRisk AssessmentTime-to-Treatment03 medical and health sciencesInternal medicinemedicineHumansAcute Coronary SyndromePandemicsRetrospective StudiesAgedPhysicians'SARS-CoV-2business.industryRisk FactorCOVID-19 myocardial infarction percutaneous coronary interventionpercutaneous coronary interventionPercutaneous coronary interventionCOVID-19*myocardial infarctionmedicine.diseasePractice Patterns Physicians'/trendsST Elevation Myocardial Infarctionbusiness
researchProduct

Hypoxia-Inducible Factor 2α Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster

2016

Contains fulltext : 172720.pdf (Publisher’s version ) (Open Access) Recently, activating mutations of the hypoxia-inducible factor 2alpha gene (HIF2A/EPAS1) have been recognized to predispose to multiple paragangliomas (PGLs) and duodenal somatostatinomas associated with polycythemia, and ocular abnormalities. Previously, mutations in the SDHA/B/C/D, SDHAF2, VHL, FH, PHD1, and PHD2 genes have been associated with HIF activation and the development of pseudohypoxic (cluster-1) PGLs. These tumors overlap in terms of tumor location, syndromic presentation, and noradrenergic phenotype to a certain extent. However, they also differ especially by clinical outcome and by presence of other tumors o…

AdultMale0301 basic medicineOriginal articleCancer ResearchAdolescentMicroarraySDHBSDHABiologylcsh:RC254-282Oxidative PhosphorylationParagangliomaYoung Adult03 medical and health sciences0302 clinical medicineParagangliomaBasic Helix-Loop-Helix Transcription FactorsmedicineJournal ArticleCluster AnalysisHumansChildHypoxiaAgedGeneticsGene Expression ProfilingVascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]Middle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePhenotypeGene Expression Regulation NeoplasticGene expression profiling030104 developmental biologyHypoxia-inducible factors030220 oncology & carcinogenesisMutationFemaleSDHDTranscriptomeProtein BindingNeoplasia
researchProduct

Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study

2018

BACKGROUND Cirrhosis is associated with morpho-functional cardiovascular alterations. AIMS To detect early features of cardiovascular damage in HCV-compensated cirrhotic patients using myocardial deformation indices and carotid arterial stiffness, and, further, to evaluate their short-term behaviour after HCV eradication with direct antiviral agents (DAAs). METHODS Thirty-nine consecutive patients with HCV cirrhosis, without previous cardiovascular events, were studied and matched for age, gender and cardiovascular risk factors to 39 controls without liver or cardiovascular disease. Patients and controls underwent a baseline echocardiographic evaluation including global longitudinal strain …

medicine.medical_specialtyCirrhosisSettore MED/09 - Medicina InternaHepatologybusiness.industryGastroenterologyHepatitis C030204 cardiovascular system & hematologycardiovascular damage cirrhosis HCV global longitudinal strainmedicine.disease03 medical and health sciencesLiver disease0302 clinical medicineInternal medicineDiabetes mellitusArterial stiffnessCardiologyMedicine030211 gastroenterology & hepatologyPharmacology (medical)businessProspective cohort studyPulse wave velocitySubclinical infection
researchProduct

SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study

2021

Abstract Background Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18–49, 50–69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results NNVs were more favourable in su…

MaleCOVID-19 Vaccinesafe surgery; vaccination modelling; COVID-19Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]MULTICENTERComorbidity030230 surgery0302 clinical medicinephase 3 clinical trial (topic)Case fatality rateProspective StudiesSARS-CoV-2 Vaccination Safe surgeryCOVID-19/epidemiologySARS-CoV-2 ; vaccination ; safe surgeryeducation.field_of_studycase fatality rateVaccinationVaccinationAdolescent; Adult; Aged; COVID-19; COVID-19 Vaccines; Comorbidity; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Postoperative Complications; Preoperative Period; Prospective Studies; SARS-CoV-2; Vaccination; Young Adulthealth care policyElective Surgical Procedures030220 oncology & carcinogenesisvaccination modellingPreoperative PeriodCOVID-19; SARS-CoV-2; cancer; vaccination; outcome; mortality; infection; modellingCohort studyprospective studyHumanmedicine.medical_specialtyArticle03 medical and health sciencesSARS-CoV-2 vaccinationSDG 3 - Good Health and Well-beingCOVID-19 Vaccines/pharmacologyHumansVaccination/methodsElective surgeryeducationAgedScience & TechnologyElective Surgical Procedureadult; aged; Article; cancer grading; cancer surgery; case fatality rate; computer assisted tomography; elective surgery; female; follow up; health care policy; human; incidence; infection rate; infection risk; major clinical study; male; middle aged; mortality; outcome assessment; phase 3 clinical trial (topic); preoperative care; prospective study; sensitivity analysis; seroprevalence; Severe acute respiratory syndrome coronavirus 2; vaccination; young adult; COVID-19; COVID-19 Vaccines; Comorbidity; Elective Surgical Procedures; Postoperative Complications; Preoperative Period; SARS-CoV-2; Vaccination; surgery.Cura preoperatòriamajor clinical studymortalityinfectionProspective StudieincidenceSurgeryHuman medicinePostoperative Complication610 Medizin und GesundheitAcademicSubjects/MED00910Settore MED/18 - CHIRURGIA GENERALESettore MED/29 - CHIRURGIA MAXILLOFACCIALEcomputer assisted tomographyESTUDOS PROSPECTIVOSsurgerysafe surgeryPostoperative Complicationssensitivity analysisSevere acute respiratory syndrome coronavirus 2preoperative careVacunacióProspective cohort studyseroprevalenceIncidence (epidemiology)covidElective Surgical Procedures/methodsMiddle Agedcancer gradingCOVID vaccinationoutcome/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingSARS-CoV-2; vaccination; surgeryOriginal ArticleFemalecancer surgeryAcademicSubjects/MED00010Life Sciences & BiomedicineAdultCOVID-19 VaccinesAdolescentinternational prospective cohort studyPostoperative Complications/prevention & controlPopulationinfection rateSARS-CoV-2/immunologyNOmodellingYoung Adultmedicinefollow upcancerddc:610infection riskoutcome assessmentLS7_4business.industrySARS-CoV-2Number needed to vaccinatePreoperative careCOVID-193126 Surgery anesthesiology intensive care radiologySettore MED/18Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]elective surgeryEmergency medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe British Journal of Surgery
researchProduct

Relationship between circulating E-selectin, DD genotype of angiotensin-converting-enzyme, and cardiovascular damage in central obese subjects

2003

Fifty-six young central obese patients were investigated to evaluate relationships between soluble E-selectin (sE-S), angiotensin-converting enzyme (ACE) gene polymorphism, left ventricular function and structure, and carotid morphology by determination of sE-S and ACE genotypes. Our results indicated that central obese subjects with concomitant higher levels of sE-S and ACE DD genotype may be characterized by early cardiovascular alterations and then considered a particular subset of subjects at higher risk of cardiovascular disease.

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina Internaangiotensin-converting-enzyme cardiovascular damageGenotypeArteriosclerosisEndocrinology Diabetes and MetabolismBlood PressureDiseasecentral obese subjectsPeptidyl-Dipeptidase ABody Mass Indexcirculating E-selectin genotype; angiotensin-converting-enzyme cardiovascular damage; central obese subjectsEndocrinologyRisk FactorsInternal medicineGenotypeE-selectinmedicineHumansInsulinObesityAllelesbiologyVentricular functionHemodynamicsHeartAngiotensin-converting enzymeGlucose Tolerance TestSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheIsoenzymesCarotid ArteriesEndocrinologyCardiovascular DiseasesEchocardiographyConcomitantbiology.proteinRegression AnalysisFemaleObese subjectsGene polymorphismE-Selectincirculating E-selectin genotypeMetabolism
researchProduct

SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study

2021

SARS-CoV-2 has been associated with an increased rate of venous thromboembolism in critically ill patients. Since surgical patients are already at higher risk of venous thromboembolism than general populations, this study aimed to determine if patients with peri-operative or prior SARS-CoV-2 were at further increased risk of venous thromboembolism. We conducted a planned sub-study and analysis from an international, multicentre, prospective cohort study of elective and emergency patients undergoing surgery during October 2020. Patients from all surgical specialties were included. The primary outcome measure was venous thromboembolism (pulmonary embolism or deep vein thrombosis) within 30 da…

Malepulmonary embolismInternationalitySettore MED/18 - CHIRURGIA GENERALEDeep veinVascular damage Radboud Institute for Health Sciences [Radboudumc 16]infectious diseasesCardiovascularSARS‐CoV‐2surgeryCOVID-19 ; SARS-CoV-2 ; deep vein thrombosis ; pulmonary embolism ; venous thromboembolismCohort StudiesPostoperative ComplicationsAnesthesiologyMedicine and Health SciencesProspective Studies610 Medicine & healthProspective cohort studyLung11 Medical and Health SciencesConfoundingHematologyMiddle AgedThrombosis17 Psychology and Cognitive SciencesCOVID-19; deep vein thrombosis; pulmonary embolism; SARS-CoV-2; venous thromboembolismPulmonary embolismCOVID-19; SARS-CoV-2; deep vein thrombosis; pulmonary embolism; venous thromboembolism.medicine.anatomical_structureCohortCOVID-19/complicationsPostoperative Complications/etiologyOriginal ArticleFemalePatient SafetyLife Sciences & BiomedicineCOVID-19; SARS-CoV-2; deep vein thrombosis; pulmonary embolism; venous thromboembolismHumanAdultmedicine.medical_specialtyAdolescentClinical Sciencesvenous thromboembolism610 Medicine & healthGlobalSurg CollaborativeVenous Thromboembolism/etiologydeep vein thrombosisNOCOVIDSurg CollaborativeYoung AdultMedicine General & InternalAge DistributionClinical ResearchCOVID‐19General & Internal MedicinemedicineHumansSex DistributionAgedScience & Technologybusiness.industrySARS-CoV-2PreventionNeurosciencesdeep vein thrombosiCOVID-19PneumoniaOdds ratioOriginal Articlesmedicine.diseaseSurgeryReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Prospective StudieGood Health and Well BeingAnesthesiology and Pain MedicineHuman medicinePostoperative ComplicationCohort StudiebusinessVenous thromboembolism[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct